Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022

- Recognition Marks Alnylam’s Eighth Year in a Row on this Prestigious List, and the Second Consecutive Year Ranking #1 -

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2022 Top Places to Work in the “Largest Employer” category. This marks the second year in a row Alnylam’s takes the top spot in the Largest Employer category (> 1,000 employees).

“I’m immensely proud of our team as we reach our eighth consecutive year on Boston Globe’s Top Places to Work,” said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. “To be ranked first on the list two years running is a testament to our commitment to excellence. When you build an atmosphere that’s diverse, equitable, inclusive, and full of high-performing, challenge-hungry people looking to change the world, good things happen.”

Companies named to the Top Places to Work list are chosen by the people who best understand the workplace environment: the employees. Employees complete an anonymous, research-backed survey assessing categories including their company’s direction, execution, connection, management, work, pay and benefits. The list spotlights companies that support employees both in and out of the office, including caregiving, mental health, and other out-of-office needs.

The Top Places to Work survey is completed by 90,000 employees, across 381 different companies in Massachusetts. The winners share key traits, including offering more flexibility to continue working remotely, tracking progress on efforts to support a diverse workforce, and, above all, remembering to have some fun along the way. This honor comes shortly after Alnylam’s second-place ranking on Science Magazine’s 2022 Top Employer Survey.

About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), GIVLAARI^® (givosiran), OXLUMO^® (lumasiran), AMVUTTRA^® (vutrisiran) and Leqvio^® (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.